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Available online xxxxBackground: Pressure ulcers (PUs) are complications of serious acute/chronic illness. Specialist mattresses used
for prevention lack high quality effectiveness evidence. We aimed to compare clinical and cost effectiveness of
2 mattress types.
Methods:Multicentre, Phase III, open, prospective, parallel group, randomised controlled trial in 42 UK second-
ary/community in-patient facilities.
2029 high risk (acutely ill, bedfast/chairfast and/or Category 1 PU/pain at PU site) adult in-patients were
randomised (1:1, allocation concealment, minimisation with random element) factors including: centre, PU sta-
tus, facility and consent type. Interventions were alternating pressure mattresses (APMs) or high specification
foam (HSF) for maximum treatment phase 60 days. Primary outcome was time to development of new PU Cat-
egory ≥2 from randomisation to 30 day post-treatment follow-up in intention-to treat population. Trial registra-
tion: ISRCTN 01151335.
Findings: Between August 2013 andNovember 2016,we randomised 2029 patients (1016 APMs: 1013HSF) who
developed 160(7.9%) PUs. Therewas insufficient evidence of a difference between groups for time to newPUCat-
egory ≥2 Fine and Gray Model Hazard Ratio HR= 0.76, 95%CI0.56–1.04); exact P = 0.0890; absolute difference
2%). Therewas a statistically significant difference in the treatment phase time to event sensitivity analysis, Fine and
Gray model HR= 0.66, 95%CI, 0.46–0.93; exact P = 0.0176); 2.6% absolute difference). Economic analyses indi-
cate that APM are cost-effective.
There were no safety concerns.
Interpretation: In high risk (acutely ill, bedfast/chairfast/Category 1 PU/ pain on a PU site) in-patients, we found in-
sufficient evidence of a difference in time to PU development at 30-day final follow-up, which may be related to a
low event rate affecting trial power. APMs conferred a small treatment phase benefit. Patient preference, low PU
incidence and small group differences suggests the need for improved targeting of APMswith decisionmaking in-
formed by patient preference/comfort/rehabilitation needs and the presence of potentially modifiable risk factors
such as being completely immobile, nutritional deficits, lacking capacity and/or altered skin/Category1 PU.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pressure ulcers (PUs) have detrimental impacts on patients' physi-
cal, social and psychological health including increased care burden,-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
Research in context
Evidence before this study
Pressure-relievingmattresses are a key component of pressure
ulcer prevention practice and lack of evidence of comparative ef-
fectiveness may lead to widespread adoption of ‘high tech’ solu-
tions (vs ‘low tech’) without demonstrated patient benefit. A
Cochrane systematic review of support surfaces was available at
trial inception and updated in 2015. The latter identifies 5
Randomised Controlled Trials (RCTs) demonstrating evidence that
a ‘low-tech’mattress type, High Specification Foam (HSF) confers
benefit over ‘standard’ hospital foam mattresses (overall relative
risk reduction of 60% (95%Confidence Interval (CI) 26% to 79%),
hence they are recommended in national and international guide-
lines as a minimum prevention intervention for patients at risk of
Pressure Ulcer development. The Cochrane review also identified
10RCTs comparing a ‘high-tech’ groupof interventions, (Alternat-
ing Pressure Mattresses (APMs)) versus HSF/other constant low
pressure mattresses and a meta-analysis found no evidence of a
difference (9 trials, overall relative risk of developing PU with
APM 0.85 (95%CI 0.64 to 1.13)). However, only one RCT directly
compared APMs and HSF plus 4 hourly turning and found no evi-
dence of a difference. Despite the lack of evidence APMs are in
common use for prevention of pressure ulcers.
Qualitative data from one large RCT and feedback from the
PressureUlcer Research ServiceUserNetwork (PURSUN) suggests
some patients do not like APMs (due to pump noise/soft air cells
impacting upon sleep, creating an unsafe feeling, restricting
movement, exacerbating existing balance/mobility problems
and increasing care burden/reducing ability to self-move).
A research recommendation from the National Institute of
Health and Care Excellence (NICE), uncertainty of clinical and
cost effectiveness, clinicians and patient preferences and a consid-
erable difference in unit costs of both these most commonly used
types of mattresses confirmed that an RCT was necessary.
Added value of this trial
PRESSURE 2 is the largest pragmatic RCT of pressure relieving
mattresses undertaken world-wide and the only direct compari-
son of ‘high tech’ APMs and ‘low tech’ HSF. We report time to de-
velopment of new Category ≥2 PUs and cost effectiveness to
30 days post treatment. Our trial provides approximately 80% of
the data for the comparison of APMs and HSF, with 160 new Cat-
egory 2 PU events in 2029 patients. There was insufficient evi-
dence of a difference between APM and HSF in time to event at
the end of trial follow-up: a pre-planned treatment phase sensi-
tivity analysis identified early benefit of APM vs HSF, which di-
minished in the long-term/primary outcome.
This is the first trial to compare mattress safety and report de-
tailed reasons for non-compliance which demonstrated no differ-
ences in the safety profile of APMs and HSF (i.e., ruled out harm),
but compliance data highlighted that more patients requested a
change from APM due to comfort or to aid movement compared
to HSF.
Finally, this is the first study in the field to include an explor-
atory moderator analysis to assess potential modifiable factors
bymattress group interactions in the primarymodel and these in-
cluded altered and Category 1 skin status, complete immobility,
nutritional deficits and lack of capacity.
Implications of all the available evidence
In patients who were at high risk of PU development: acutely
ill in-patients, who were bedfast/chairfast and/or had an existing
Category 1 PU (or pain on a PU site), we found insufficient evi-
dence of a difference in time to PU development at the end of
trial follow-up. However, APMs did confer a small treatment
phase time to event benefit. Given the small absolute differences
during treatment (2.6%) and long-term follow-up (2%), patient
APM compliance and very low PU incidence rate observed
(7.9%), there is a trade-off between using APMs and HSF. We rec-
ommendwork on improving the personalisation ofmattress type.
This should take into account patient preferences, rehabilitation
needs and the presence of risk factors which may be modifiable.
Those gaining more potential benefit from APM are likely to be
completely immobile, have nutritional deficits, lack capacity
and/or have altered skin/Category1 PU.
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symptoms of pain, exudate and odour [1]. PUs are prevalent in the
health-care sector [2] and as the elderly population increases and ad-
vances in medical care lead to increased long-term disability burden
and complexity in patient management, improving the evidence
base for improvements in their prevention is a priority. As well as
high personal costs incurred by patients there are also high financial
costs incurred by healthcare funders and providers in the treatment
of PUs due to increased length of hospital stay, hospital admission,
community nursing, treatments (reconstruction surgery/ mat-
tresses/ dressings/ technical therapies) and complications (serious
infection) [3].
They manifest when mechanical load applied to soft tissues causes
cell deformation leading to cell membrane rupture and/or impairment
of the blood supply and tissue ischaemia, both resulting in tissue dam-
age [4].
A priority in clinical practice is prevention of PUs through reposi-
tioning (to intermittently completely off-load high risk skin areas) and
provision of specialist mattresses/cushions to reduce mechanical load
[5,6]. In relation to specialist mattresses, systematic review evidence
[7] supports guideline recommendations that high specification foam
(HSF) mattresses are used as a minimum for high risk patients to pre-
vent PUs [5,6]. TheMcInnes et al. review [7] identified 11 RCTs compar-
ing alternating pressure mattresses (APMs) with constant low pressure
mattresses and a meta-analysis of 10 showed no evidence of a
difference.
Despite the lack of evidence APMs are recommended in guidelines
for patients where HSF is failing [5] or repositioning is not possible [6]
and they are in widespread clinical use.
However, lived experience studies [1], secondary trial data [8]
and feedback from the PU Research Service User Network (PURSUN)
(http://medhealth.leeds.ac.uk/pursun accessed 06.08.18) suggests
some patients do not like APMs (due to pump noise/soft air cells
impacting upon sleep, creating an unsafe feeling, restricting move-
ment, exacerbating existing balance/mobility problems and increas-
ing care burden/reducing ability to self-move [8]. More recently a
network meta-analysis reported that APMs had the lowest probabil-
ity of being the most comfortable compared to other mattress types
[9].
To address clinical uncertainty this pragmatic real world evalua-
tion was designed to compare the clinical and cost effectiveness of
two functionally distinct mattress types: ‘high tech’ alternating pres-
sure mattresses (APMs) and ‘low tech’ high specification foam (HSF)
[7].
The primary objective was to compare time to developing a new PU
Category ≥2 by 30 days post end of treatment phase. Secondary objec-
tives were to compare: time to developing a new PU Category ≥1;
time to developing a new PU Category ≥3; time to healing of all pre-
existing Category 2 PUs; mattress compliance; safety; impact on health
related quality of life and incremental cost effectiveness.ieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
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2.1. Study Design
Thiswas designed as amulticentre, Phase III, open, prospective, dou-
ble triangular group sequential, parallel group, randomised controlled
trial (RCT), with two planned interim analyses providing the possibility
of early stopping for either futility or inferiority. The trial protocol is
published [10] and summary methods detailed.
The trial, approved by Leeds West Research Ethics Committee (13/
YH/0066), was monitored by an independent Trial Steering Committee
(TSC) and Data Monitoring Committee (DMC).Table 1
Additional skin classifications.
Category Description
Category A
Alterations to
intact skin
Alterations to intact skin. Please specify with sub-category code:
001 = Blanching redness
which persists
011 = Papery thin
002 = Bruising – red hue 012 = Cracks/calloused
003 = Bruising – purple
hue
013 = Spongy
004 = Scar 014 = Macerated2.2. Participants
The trial was promoted to centres through national networks and
any organisation with sufficient access to trial eligible mattresses (see
eDocument 1) and electric profiling beds were able to take part in the
trial.
Patients were recruited from adult secondary care and community
in-patient acute admission facilities in the UK (facilities are defined in
eDocument 2). Prior to recruitment patients could be laying on any
type of mattress. Consent was obtained though written/witnessed ver-
bal consent or consultee agreement (see eDocument 3).
Patients were eligible if theywere: in-patient with evidence of acute
illness [10]; ≥ 8 years; expected stay ≥5 days; expected to comply with
follow-up; on electric profiling bed-frame; high PU risk due to at least
one of following:
a) Braden Activity score 1/2 AND Mobility score 1/2 [11,12]
b) Category 1 PU [12]
c) Localised skin pain on a healthy/altered/Category 1 pressure area
[13].
Patients were excluded if they: had previously participated; cur-
rent/previous PU Category ≥3; planned ICU admission; unable to re-
ceive intervention; outwith mattress weight limits (b45 kg or
N 180Kg); ethically inappropriate e.g. thought to be in the last few
days of their life.
Since a large proportion of patients suffering from or at risk of PUs
have cognitive impairment and this impacts upon understanding
and compliance with repositioning and self-care, including ability
to reposition independently using the electric profiling beds, inclu-
sion of patients who lacked capacity was necessary to ensure the
study population was generalisable to a usual clinical population.
Ethical approval was obtained to include patients who lacked
capacity.005 = Oedema 015 = Scratches
006 = Cellulitis 016 = Rash
007 = Lymphodema 017 = Scab
008 = Discoloration –
ischaemia
018 = Induration
009 = Discoloration –
cyanosis
019 = Heat
010 = Dry/flaky 999 = None of the above, please
describe
Category N/A
Not applicable
Specify with sub-category code:
001 = Amputation 007 = Device-related ulcer
002 = Bandage in situ 008 = Surgical wound/bruising
003 = Cast in situ 009 = Traumatic
wound/bruising
004 = Dressing in situ 010 = Dermatological skin
condition e.g. eczema
005 = Incontinence
associated dermatitis
011 = Unable to assess
006 = Other chronic wound 999 = None of the above, please
describe2.3. Randomisation and Masking
Participants were randomised centrally (24 h automated telephone
system, ensuring allocation concealment) on a 1:1 basis using
minimisation (with random element) andminimisation factors: centre,
PU status, type of facility, and type of consent. Following randomisation
the patient was expected to be transferred to the allocated mattress
within 24 h. Full details of randomisation and allocation procedures
are given in eDocument 4.
Blinding of the research and clinical staff or patientswas not possible
due to the appearance of the mattresses. Assessment of risk of bias of
the primary endpoint was done with central blind review of photo-
graphs and a 10% sample of patients who had skin assessments by a
practitioner blinded to previous assessments was performed. Details
of methods are provided elsewhere [14].Please cite this article as: J. Nixon, I.L. Smith, S. Brown, et al., Pressure Rel
Clinical and Health ..., , https://doi.org/10.1016/j.eclinm.2019.07.0182.4. Procedures
Patients were allocated to APM or HSF mattress for a maximum
60 day treatment phase (or until discharge, or no longer at risk), in con-
junction with electric profiling bed frames. Treatment follow-up was
twice weekly to day 30 and weekly from day 31–60 and there was a
post treatment 30 day final follow-up.
Mattress specifications were defined (eDocument 1) and utilised
from usual hospital supplies, maximising generalisability.
Participant recruitment and assessments were conducted by trained
dedicated Clinical Research Nurse/Practitioners (CRN/P), employed by
the local centre and independent of the ward teams. The assessment
schedule was as follows:
Baseline only: risk factors were recorded using the PU Minimum
Data Set [12,15].
Baseline and follow-up visits: a) skin status, assessed on 14 anatom-
ical sites including PU classification [6], additional descriptors of alter-
ations to intact skin and skin site exclusions (Table 1 and eDocument
6) [12] and pain [13], b) PU preventionmeasures (e.g. repositioning fre-
quency) and c) expected adverse events/serious adverse events (AEs/
SAEs) including death, hospital re-admission, device-related ulcers
and falls and ‘related’ and ‘unexpected’ SAEs (RUSAEs).
Daily: mattress compliance (including which mattress the patient
was on and whether, if it had dual function, it was in APM mode) was
recorded during the treatment phase.
Baseline, week 1, week 3 and post treatment 30 day final follow-up:
a generic QOL instrument EuroQol-5Dimension-5 Level (EQ-5D-5 L)
[16] and condition specific utility measure Pressure Ulcer-Quality of
Life-Utility Index (PU-QOL-UI) [17,18] were researcher administered
with a healthcare resource utilisation questionnaire (combining
healthcare records and patient reported sources).2.5. Outcomes
The primary outcomewas time to developing a new PU Category ≥2
from randomisation to 30 days from the end of the treatment phase
(maximum of 90 days).ieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
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1. Time to developing a new PU Category ≥3 from randomisation to
trial completion
2. Time to developing a new PU Category ≥1 from randomisation to
trial completion
3. Time to healing of all pre-existing Category 2 PUs from
randomisation to trial completion
4. Mattress change during the treatment phase
5. Adverse events
Secondary objectives (Health Economic)
1. Health related quality of life (QOL) using SF-12 and PU-QoL-P
instruments
2. Incremental cost-effectiveness of APM compared to HSF from the
perspective of the health and social care sectors using EQ-5D-5 L
and health and social care resource utilisation questionnaire
PUs were classified using the 2009 National Pressure Ulcer Advisory
Panel/European Pressure Ulcer Advisory Panel (NPUAP/EPUAP) [19]
system. In the absence of a PU, additional descriptors were recorded in-
cluding ‘healthy intact skin’, alterations to intact skin (referred to as Cat-
egory A for data recording purposes) and ‘not applicable’ as detailed in
Table 1.
2.6. Sample Size and Statistical Analysis
588 events (~2954 patients) were required for 90% power, 5% differ-
ence (APM 18% vs HSF 23%, corresponding hazard ratio 0.759), 5% 2-
sided significance level, 6% loss to follow-up [8,13,20] accounting for
multiplicity in interim analyses using Lan-DeMets α and β spending
functions [21]. Event driven interim analyses were planned (300 and
445 events) and a Value of Information (VOI) Analysis if futility bound-
ary was crossed; futility boundaries were non-binding.
The trial recruited participants at a much slower rate than antici-
pated and an unplanned interim analysis and VOI Analysis using confi-
dential trial data was requested by the funder and conducted in
November/December 2015 on 909 participants. Unblind analyses
were reviewed by the DMC and remained confidential. The DMC in-
formed the Independent TSC that the event rate was much lower
(9.9%) than originally estimated. The DMC and TSC asked the TrialMan-
agement Group (TMG) who remained blind to the event rate, to con-
sider the minimum clinically relevant differences on varying centred
event rates of 15%, 10% and 5%. The preferred TMG option was a funded
extension to detect absolute differences of 3.75%, 3.3% and 2.5% (relative
differences of 25%, 33.3% and 50%) respectively, which were considered
to be theminimum clinically important differences. The TMG also noted
that a no cost extension to detect absolute differences of 5%, 4% and 3%
(relative difference of 33.3%, 40% and 60%) respectivelywere considered
of clinical relevance. The funder agreed to a no cost recruitment exten-
sion with a final minimum recruitment target of 1996 patients, under a
revised assumption of an overall event rate of 10%, absolute difference
of 4% (corresponding HR of 0.652) with 80% power, requiring 172
events to be observed. This resulted in the trial design being modified
to have one final analysis. Further details of the review process, analysis
and recommendations can be found in eDocument 5.
Analyses were performed using SAS version 9.4 (SAS Institute Inc.,
Cary, NC, USA) and pre-approved statistical analysis plan (eDocument
6). All participants recruited were included using ‘Intention-To-Treat’
(ITT) and analysed by randomised allocation.
The Fine and Gray [22]model (accounting for death andwithdrawal
due to clinical condition as competing risks) was fitted to the primary
and secondary time to event endpoints and the planned treatment
phase sensitivity analysis with adjustment for minimisation factors (ex-
cept centre), presence of pain and presence of a condition affecting pe-
ripheral circulation; a likelihood ratio test was used to assess the effectPlease cite this article as: J. Nixon, I.L. Smith, S. Brown, et al., Pressure Rel
Clinical and Health ..., , https://doi.org/10.1016/j.eclinm.2019.07.018of mattress group. Corresponding hazard ratios (HR), 95% confidence
intervals (CI) and P-values are reported, and cumulative incidence of
PU Category ≥2 development presented by mattress group.
AEs/SAEs and RUSAEs were summarised using descriptive statistics.
Analysis of data from the ‘Per Protocol’ population was undertaken.
An exploratory moderator analysis was also undertaken to assess
potential risk factor by mattress group interactions in the primary
model.
A mediator analysis was planned to identify potential mediators,
such as mattress compliance and patient repositioning, however
methods for competing risks data are currently under developed and
therefore only descriptive summaries were produced.
To meet the health economic objectives, an ITT analysis used quality
adjusted life years (QALYs) as the main outcome and adopted the per-
spective of the UK National Health Service (NHS) and Personal Social
Services (PSS). The NICE £20,000 per QALY gained threshold was used
to determined cost-effectiveness. Utility values were derived from the
EQ-5D-5L [23], and costs were estimated using the UK tariff [23]. Multi-
ple imputationwas used to provide data for all patients and incremental
cost effectiveness ratios (ICERs) reported. Costs and outcomes were ad-
justed for baseline imbalances using multiple regression analysis. Ad-
justment was made by utility at baseline (for outcomes only), PU
status, setting, peripheral circulation andpresence of pain. Sampling un-
certainty was determined via a probabilistic sensitivity analysis (PSA)
using a non-parametric bootstrap [24–26]. Additional sensitivity analy-
ses were undertaken using QALYs estimated from the PUQOL-UI and
complete cases only [18].
ISRCTN 01151335 URL: https://www.isrctn.com/search?q=
01151335
2.7. Role of Funding Source
This projectwas funded by theNational Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme (project
number 11/36/33). The funder monitored recruitment, requested an
unplanned interim and VOI analysis, reviewed the VOI analysis and
the recommendations of the TSC and DMC for trial continuation and
made the final decision for an unfunded time extension to meet the re-
vised minimum of 1996 participants.
3. Results
Between 1st August 2013 and 30th November 2016, 15,277 patients
were screened (Fig. 1) from 39 English NHS Trusts/Scottish Health
Boards (total 47 centres, comprising 25 teaching hospitals, 13 general
hospitals and 9 community hospitals). Of those screened, 5077(33.2%)
patients were eligible of whom 2068(40.7%) consented and 2030
(40.0%) were randomised to APMs (1017, 50.1%) and HSF (1013,
49.9%), Fig. 1.
Screened and randomised populations were similar in age, gender
and ethnicity but not by ward allocated mattress type. At screening,
7640(50.0%) patients were on APM or other ‘high tech’ and 7462
(48.8%) patients were on HSF or other ‘low tech’, whereas, of those
randomised 868(42.8%) were on APM and 1149(56.6%) were on HSF,
reflecting greater staff unwillingness to randomise patients already pro-
vided with an APM (Table 3).
Patient disposition was balanced across groups including, with-
drawals (APM 6.1%, HSF 5.6%) and deaths (APM 8.1%, HSF 8.3%)
(Fig. 1). One patient randomised twice, was withdrawn and the second
randomisation excluded from the ITT population (n = 2029).
Patient characteristics and pre-randomisation preventative care in-
terventions were balanced across groups (Table 2, Table 3 and
Table 7a in eDocument 7).
The trial comprised largely of elderly patients (median 81 years,
range 21–105), 1119 (55.2%) were female and 1992 (98.2%) of whiteieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
Fig. 1. Consort diagram.
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Table 2
Baseline characteristics of the intention-to-treat population.
Attribute APM
n = 1016
HSF
n = 1013
Overall
n = 2029
Gender
Male 462(45.5%) 445(43.9%) 907(44.7%)
Female 553(54.4%) 566(55.9%) 1119(55.2%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Age (years)
Mean (S.D.) 77.8(13.42) 78.2(12.87) 78.0(13.1)
Median (range) 81(21.1105) 81(21.9101) 81(21,105)
IQR (71.3,87.0) (71.9,87.2) (71.6,87.1)
Missing 0 0 0
Ethnicity
White 1000(98.4%) 992(97.9%) 1992(98.2%)
Mixed race/non-white 15(1.5%) 19(1.9%) 34(1.7%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Medical speciality
Medical 641(63.1%) 669(66.1%) 1310(64.6%)
Surgical 83(8.2%) 72(7.1%) 155(7.6%)
Orthopaedics and trauma 233(22.9%) 220(21.7%) 453(22.3%)
Oncology 21(2.1%) 16(1.6%) 37(1.8%)
Critical care 10(1.0%) 6(0.6%) 16(0.8%)
Neurosciences 17(1.7%) 15(1.5%) 32(1.6%)
Spinal injury 8(0.8%) 9(0.9%) 17(0.9%)
Other 2(0.2%) 2(0.2%) 4(0.2%)
Missing 1(0.0%) 4(0.3%) 5(0.2%)
Consent type
Written 706(69.5%) 696(68.7%) 1402(69.1%)
Witnessed verbal 151(14.9%) 152(15.0%) 303(14.9%)
Consultee agreement 159(15.6%) 163(16.1%) 322(15.9%)
Missinga 0(0.0%) 2(0.2%) 2(0.1%)
Healthcare setting
Secondary care hospital 710(69.9%) 704(69.5%) 1414(69.7%)
Community hospital 191(18.8%) 188(18.6%) 379(18.7%)
NHS intermediate care/
rehabilitation facility
115(11.3%) 119(11.7%) 234(11.5%)
Missingb 0(0.0%) 2(0.2%) 2(0.1%)
Days between admission to
randomising
Mean (S.D.) 12.7(20.27) 13.3(21.23) 13.0(20.8)
Median (range) 6(0.0,306) 7(0.0,388) 7(0,388)
IQR (3.0,15.0) (3.0,17.0) (3.0,16.0)
Missing 1 2 3
Standard deviation (SD), Inter-Quartile Range (IQR).
a These were entered on the 24 h system as written consent, and therefore included in
the analyses.
b These were entered on the 24 h system as Secondary care hospital, and therefore in-
cluded in the analyses,
Table 3
Baseline PU prevention interventions.
Interventions APM
n = 1016
HSF
n = 1013
Overall
n = 2029
Current mattress type
HSF or other ‘low tech’ 575(56.6%) 574(56.7%) 1149 (56.6%)
APM or other ‘high tech’ 435(42.8%) 433(42.7%) 868(42.8%)
Missing 6(0.6%) 6(0.6%) 12(0.6%)
Frequency of repositioning in last
24 h
More frequently than 2 hourly 148(14.6%) 146(14.4%) 294(14.5%)
2–3 hourly 473(46.6%) 494(48.8%) 967(47.7%)
4–5 hourly 333(32.8%) 307(30.3%) 640(31.5%)
6–7 hourly 36(3.5%) 48(4.7%) 84(4.1%)
Less frequently than 8 hourly 20(2.0%) 12(1.2%) 32(1.6%)
Missing 6(0.6%) 6(0.6%) 12(0.6%)
Time spent sat out of bed in last 24
h
N/A i.e. bedfast 270(26.6%) 271(26.8%) 541(26.7%)
Less than 2 h 91(8.9%) 90(8.9%) 181(8.9%)
2–3 h 134(13.2%) 134(13.2%) 268(13.2%)
4–5 h 178(17.5%) 183(18.1%) 361(17.8%)
6–7 h 125(12.3%) 128(12.6%) 253(12.5%)
More than 8 h 207(20.4%) 191(18.9%) 398(19.6%)
Missing 11(1.1%) 16(1.6%) 27(1.3%)
Type of cushion
Standard chair only 203(27.3%) 206(27.9%) 409(27.6%)
High tech specialist cushion 56(7.5%) 52(7.0%) 108(7.3%)
Low tech specialist cushion/
chair with integral pressure
relief
434(58.3%) 429(58%) 863(58.2%)
Pillow 45(6.1%) 47(6.4%) 92(6.2%)
Missing 6(0.8%) 5(0.7%) 11(0.7%)
Total (number of patients who sat
out)
744(100%) 739(100%) 1483(100%)
Participant on electronic profiling
bedframe
Yes 1012(99.6%) 1008(99.5%) 2020(99.6%)
No 3(0.3%) 3(0.3%) 6(0.3%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Adjuvant devices and dressing
Yes 143(14.1%) 141(13.9%) 284(14.0%)
No 867(85.3%) 865(85.4%) 1732(85.4%)
Missing 6(0.6%) 7(0.7%) 13(0.6%)
6 J. Nixon et al. / EClinicalMedicine xxx (xxxx) xxxethnicity. Patients were in-patients for a median of 7 (range 0–388)
days pre-randomisation.
Overall 322 (15.9%) patients lacked capacity, 909(44.8%) had a his-
tory of falls in the precedingmonth, 1961 (96.6%) had limitations to in-
dependent movement and 2003 (98.7%) and 1879 (92.6%) patients
were classified as ‘at risk’ of PU development on the PURPOSE-T and
Braden Scale respectively (Table 4). Subscales of Braden: Activity and
Mobility have been included as they were eligibility criteria.
There were high levels of skin morbidity including ‘worst’ PU/skin
status of 7.1%(n = 145) Category 2 PUs, 11.6%(n = 235) Category 1
and 66.4%(n = 1347) alterations to intact skin with 53.4%(n = 1084)
reporting pressure area related pain (Table 5).
Of 2029 ITT population, 160 (7.9%) patients developed at least one
new PU Category ≥2 with an absolute difference of 2% (APM 70
(6.9%), HSF 90(8.9%)), see Table 6 with a total of 213 new PUs Category
≥2 observed (APM, N=89, HSF, N=124). Skin sites location of all new
PUs can be found in eDocument 7b.
Where patients developed a PU Category ≥2, the median (range)
time to first new PU Category ≥2 was APM 18 days (2–86) and HSF
12days (2–94). Therewas no evidence of a difference betweenmattress
groups for the primary endpoint (time to development of PU Category
≥2) in the adjusted analysis (Fine and Gray model (HR = 0.76 (95%CI,
0.56 to 1.04; exact P = 0.0890))). Only skin status was statisticallyPlease cite this article as: J. Nixon, I.L. Smith, S. Brown, et al., Pressure Rel
Clinical and Health ..., , https://doi.org/10.1016/j.eclinm.2019.07.018significantly associated with the primary endpoint (Wald P =
0.0057); specifically, patients with a pre-existing Category 1 PU (HR
= 1.83(95% CI, 1.17 to 2.87)) and pre-existing Category 2 PU (HR =
1.83(95% CI, 1.09 to 3.09)) were more likely to develop a new Category
2 PU than those who did not have a Category 1 or 2 PU at baseline (see
Table 7). Fig. 2 represents the unadjusted cumulative incidence curves
for the primary and secondary analyses.
In the treatment phase sensitivity analysis, 132 (6.5%) developed
new PU Category ≥2 between randomisation and end of treatment
phase (APM 53(5.2%), HSF 79 (7.8%)) with a statistically significant dif-
ference observed in time to development of PU Category ≥2 in the Fine
and Gray model (HR = 0.66(95% CI, 0.46 to 0.93; exact P = 0.0176))
(see eDocument 8a).
350 (17.2%) patients reached the secondary endpoint of developing
a new PU Category ≥1 by 30 day final follow-up (APM 160(15.7%), HSF
190(18.8%)), with no evidence of a difference in the time to event (Fine
and Gray model (HR = 0.83(95% CI, 0.67 to 1.02; exact P = 0.0733)))
(see eDocument 8b).
32 (1.6%) patients reached the secondary endpoint of developing a
new PU Category ≥3 by 30 day final follow-up (APM 14(1.4%), HSF 18
(1.8%)) with no evidence of a difference in the time to event (Fine and
Gray model (HR = 0.81(95% CI, 0.40 to 1.62; exact P = 0.5530)) (see
eDocument 8c)). The number of Category ≥3 PUs were comparable by
arm (APM N= 19 vs HSF N = 21).
Of 145 patients with a pre-existing PU Category 2 (APM 70(48.3%),
HSF 75(51.7%)), healing was observed in 89 (APM 44(62.9%); HSF 45
(60.0%)) (see eDocument 8d), with no evidence of a difference in theieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
Table 4
Baseline risk factors.
Risk factor APM
n = 1016
HSF
n = 1013
Overall
n = 2029
BMI
Underweight (b18.5 kg/m2) 52(5.1%) 49(4.8%) 101(5.0%)
Normal weight (18.5 to b25
kg/m2)
455(44.8%) 392(38.7%) 847(41.7%)
Overweight (25 to b30 kg/m2) 266(26.2%) 336(33.2%) 602(29.7%)
Obese (≥30 kg/m2) 235(23.1%) 217(21.4%) 452(22.3%)
Missing 8(0.8%) 19(1.9%) 27(1.3%)
History of falls in the past month
Yes 458(45.1%) 451(44.5%) 909(44.8%)
No / not aware of any falls 554(54.5%) 559(55.2%) 1113(54.9%)
Missing 4(0.4%) 3(0.3%) 7(0.3%)
Analysis of independent
movement
Moves frequently / Major
position changes
28(2.8%) 32(3.2%) 60(3.0%)
Moves frequently / Slight
position changes
141(13.9%) 139(13.7%) 280(13.8%)
Moves occasionally / Major
position changes
110(10.8%) 110(10.9%) 220(10.8%)
Moves occasionally / Slight
position changes
624(61.4%) 621(61.3%) 1245(61.4%)
Doesn't move 109(10.7%) 107(10.6%) 216(10.6%)
Missing 4(0.4%) 4(0.4%) 8(0.4%)
Risk status recorded on PURPOSE T
Not at risk 12(1.2%) 11(1.1%) 23(1.1%)
No PU but at risk 820(80.7%) 816(80.6%) 1636(80.6%)
PU Category ≥1 or scarring from
previous PU
183(18.0%) 184(18.2%) 367(18.1%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Braden Activity subscale
Walks Frequently 13(1.3%) 9(0.9%) 22(1.1%)
Walks Occasionally 108(10.6%) 113(11.2%) 221(10.9%)
Chairfast 677(66.6%) 667(65.8%) 1344(66.2%)
Bedfast 217(21.4%) 222(21.9%) 439(21.6%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Braden Mobility subscale
No Limitation 22(2.2%) 20(2.0%) 42(2.1%)
Slightly Limited 125(12.3%) 115(11.4%) 240(11.8%)
Very Limited 790(77.8%) 797(78.7%) 1587(78.2%)
Completely Immobile 78(7.7%) 79(7.8%) 157(7.7%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Overall Braden PU risk
Not at risk (N18) 78(7.7%) 69(6.8%) 147(7.2%)
At risk (≤18) 937(92.2%) 942(93.0%) 1879(92.6%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Table 5
Skin status at baseline.
Question APM
n = 1016
HSF
n = 1013
Overall
n = 2029
Worst category of skin reported at
baseline (patient level)
Normal Skin 147(14.5%) 152(15.0%) 299(14.7%)
Category A 673(66.2%) 674(66.5%) 1347(66.4%)
Category 1 125(12.3%) 110(10.9%) 235(11.6%)
Category 2 70(6.9%) 75(7.4%) 145(7.1%)
Missing 1(0.1%) 2(0.2%) 3(0.1%)
Pressure related pain on any skin
site
Yes 577(56.8%) 584(57.7%) 1161(57.2%)
No 393(38.7%) 388(38.3%) 781(38.5%)
Unable to assess 15(1.5%) 15(1.5%) 30(1.5%)
Combination of ‘missing’ and
‘no’
6(0.6%) 6(0.6%) 12(0.6%)
Combination of ‘No’ and ‘unable
to assess
15(1.5%) 13(1.3%) 28(1.4%)
Missing 10(1.0%) 7(0.7%) 17(0.8%)
Pressure related pain on a healthy,
altered or Category 1 skin site?
Yes 541(53.2%) 543(53.6%) 1084(53.4%)
No 440(43.3%) 439(43.3%) 879(43.3%)
Unable to assess 15(1.5%) 15(1.5%) 30(1.5%)
Combination of ‘missing’ and
‘no’a
2(0.2%) 1(0.1%) 3(0.1%)
Combination of ‘No’ and ‘unable
to assessa
5(0.5%) 3(0.3%) 8(0.4%)
Missing 9(0.9%) 5(0.5%) 14(0.7%)
No skin sites reported as healthy,
altered or Category 1b
4(0.4%) 7(0.7%) 11(0.5%)
a Classified as ‘no’ in the analysis.
b Classified as ‘missing’ in the analysis.
7J. Nixon et al. / EClinicalMedicine xxx (xxxx) xxxtime to event (Fine and Gray model (HR = 1.12 (95% CI, 0.74 to 1.68;
exact P = 0.6122))).
There were no ‘RUSAEs’ and only 3 mattress related AEs reported.
Deaths (APM 8.1%, HSF 8.3%), re-admission rates (APM 8.1%, HSF 6.1%)
and fall rates (APM 14.9%, HSF 15.7%) were similar in both groups. Of
all 486 reported falls, 62.3% occurred after the treatment phase and
17.5% resulted in serious injury but none were mattress related.
Compliance with mattress allocation within 48 h of randomisation was
reported for 81.5%ofpatients in eachgroup (see eDocument9). Themedian
(range) proportion of time spent on the randomised mattress was 92%
(0–100%) APM and 100% (0–100%) HSF. Only 94 (9.3%) APM and 110
(10.9%) HSF randomised patients never received their allocated mattress.
Where allocated mattress was received, 24.1%(222/922) APM and
24.4%(220/903) HSF had at least one mattress change (eDocument 9),
with reasons for first change including mattress being uncomfortable
(APM 90(40.5%), HSF 28(12.7%)); to aid rehabilitation or movement
(APM 49 (22.1%), HSF 5(2.3%)); ward transfer (APM 40(18.0%), HSF
20(9.1%)) and clinical condition (APM 3(1.4%), HSF 130(59.1%)).
The blinded central photography sub-study [14] undertaken to es-
tablish systematic bias in endpoint assessment found high levels of
agreement in both arms and a Prevalence and Bias Adjusted Kappa sta-
tistic of 0.93 demonstrating ‘very good agreement’ of blinded photo-
graph assessments compared to un-blind clinical assessments.Please cite this article as: J. Nixon, I.L. Smith, S. Brown, et al., Pressure Rel
Clinical and Health ..., , https://doi.org/10.1016/j.eclinm.2019.07.0183.1. Per Protocol Population
The per-protocol population consisted of 1352(66.6%) patients. Pa-
tients were excluded from the per-protocol analysis for compliance
and eligibility reasons (not mutually exclusive) as follows; less than
60% compliance with allocated mattress (N = 545, 26.9%), not at high
risk of PU development (N=42, 2.1%), current or previous PU Category
≥3 (N=8, 0.4%), outsideweight limits (N= 6, 0.3%), consent formwas
not received or consent date was after randomisation (N=13, 0.6%). Of
the 1352 patients in the per-protocol population, 663(49.0%) were allo-
cated to APM and 689(51.0%) were allocated to HSF. There was no evi-
dence of a difference between mattress groups in time to development
of new PU Category ≥2 for the primary endpoint (adjusted Fine and
Graymodel HR (95%CI)= 0.79 (0.54 to 1.16), P=0.2249), absolute dif-
ference 1.2% (APM 7.2%, HSF 8.4%). In the treatment phase sensitivity
analysis a marginally significant treatment effect in time to develop-
ment of new PU Category ≥2 was observed indicating some evidence
of a difference between mattress groups (adjusted Fine and Gray
model HR (95%CI) of 0.76 (0.32 to 1.00), P = 0.0508), absolute differ-
ence 1.7% (APM 5.7%, HSF 7.4%).3.2. Moderator Analysis (Exploratory Analysis)
The results of the exploratory moderator analysis of the treatment
effects for each level of each covariate (risk factor) for the primary end-
point are presented in Fig. 3. The Forest plots present the point estimate
of the treatment effect, ln(HR), together with the corresponding 95% CI,
alongside the plot, the corresponding HR and 95% CIs. Incidence rates
observedwithin each level of risk factor are alignedwith the PU concep-
tual framework [4] and whilst there is no evidence of differential treat-
ment effects within risk factors at the 5% significance level, treatment
effects from these exploratory analyses suggest that there may be a po-
tential benefit of APM vs HSF in patients whose worst skin status wasieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
Table 6
Number of patients developing a new PU Category ≥2 at post treatment 30 day final follow-up.
Mattress New PU
Cat ≥ 2
No new PU Category ≥ 2 Baseline
Assessment
not eligible
Total
No Died Withdrawn
APM 70(6.9%) 825(81.2%) 77(7.6%) 40(3.9%) 4(0.4%) 1016 (100%)
HSF 90(8.9%) 812(80.2%) 72(7.1%) 31(3.1%) 8(0.8%) 1013 (100%)
Overall 160(7.9%) 1637(80.7%) 149(7.3%) 71(3.5%) 12(0.6%) 2029 (100%)
8 J. Nixon et al. / EClinicalMedicine xxx (xxxx) xxxassessed as altered or PU Category 1; those with mobility limitations;
those with a nutritional problem and; patients who participated via
consultee agreement.
3.3. Mediator Analysis (Exploratory Analysis)
Throughout the treatment phase at least 50% of patients in both APM
and HSF arms at each visit with complete data were repositioned 2–-
3 hourly or more frequently. However, the proportion of patients
repositioned 2–3 hourly or more frequently appears to reduce during
the treatment phase in both arms (eDocument 10).
3.4. Health Economics
The mean total health care costs of using APM was lower than HSF
(£4482; 95% CI £4438–£4526 vs £4621; 95% CI £4577–£4665; P b
0.000), this despite the APM mattress being more costly as the biggest
proportion of the costs (around 60%) correspond to in-patient care
(APM £2810.08; HSF £2888.68) (eDocument 11 Health Economic Anal-
ysis). In terms of outcomes, the mean estimated QALYs were higher for
APM than HSF (0.128; 95% CI 0.126–0.130 vs 0.127 95% CI 0.124–129; P
= 0.47). Although the negligible difference in QALYs, the difference in
costs between the two alternatives drive the cost-effectiveness towards
APM.
The results of the PSA confirm those of the deterministic analysis as
in 99% of the 10,000Monte Carlo simulations APM is cost-saving, whilst
in 77% APM it produces more QALYs than HSF. Although in some cases
(33% iterations) HSF produces more QALYs, its higher cost overcome
these gains. Therefore, the PSA estimates indicate that APM has a 99%
probability of being cost effective at a threshold of £20,000 (eDocument
11 Health Economic Analysis).
The results of the sensitivity analyses using QALYs derived from the
PUQOL-UI were in the same direction aswhen derived from the EQ-5D-
5L (eDocument Health Economic Analysis).Table 7
Time to development of new PU Category ≥2 by 30 day final follow-up.
Covariate Level of covariate Inciden
Treatment HSF 90/101
APM 70/101
Skin status No PU 115/16
PU Category 1 27/236
PU Category 2 18/145
Consent type Written 100/14
Witnessed verbal 32/303
Consultee agreement 28/322
Setting Secondary care hospital 102/14
Community hospital 34/379
NHS intermediate care/ rehabilitation facility 24/234
Pain on a healthy, altered or
PU Category 1 skin site
No 67/890
Yes 90/108
Unable to assess 1/30 (3
Missing 2/25 (8
Presence of condition affecting
peripheral circulation
No 120/15
Yes 39/455
Missing 1/7 (14
⁎ P-values obtained from corresponding likelihood ratio tests for the effect of treatment is 0
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Overall, only 7.9% of patients recruited to the PRESSURE 2 trial devel-
oped one or more new Category ≥2 pressure ulcers. The point estimate
of the hazard ratio suggests a benefit of APM over HSF but the trial was
underpowered for the primary 30 day post treatment phase endpoint
due to the lownumber of PU events and the time to event difference ob-
served was not statistically significant different between mattress
groups. All analyses were in the same direction as the primary endpoint
and the treatment phase sensitivity analysis demonstrated small but
significant early benefit of APM vs HSF. Importantly, all analyses ruled
out harm.
The long-term outcome was considered the most important for the
NHS and it appears that the early benefit of the APM in the delayed
onset of new PUs during the treatment phase, is diminished following
treatment phase cessation and can be explained by cross over, increased
population heterogeneity post-acute illness and variation in post dis-
charge prevention provision.
PRESSURE 2 is the largest randomised controlled mattress trial un-
dertaken world-wide, and results are consistent with the study by
Vanderwee [20] and colleagues who reported new Category 2 PU inci-
dence rates of 15.3% for APM and 15.6% for HSF plus turning. Our trial
provides approximately 80% of the data for the comparison of APMs
andHSF,with 160 events in 2029patients, withVanderwee [20] provid-
ing data on 69 events in 447 patients.
Despite the negligible difference in QALYs equating to around half a
quality adjusted life day, the difference in costs between the two alter-
natives drive the cost-effectiveness towards APM. Overall estimates
suggest that APM has a 99% probability of being cost-effective at a
£20,000 per QALY gained threshold.
Overall, mattress compliance was good and balanced across both
groups for numbers not receiving randomised mattress, numbers re-
ceiving randomised mattress within 2 days and median time on
randomised mattress. As such compliance was better than expectedce Reference level HR point
Estimate
HR 95% Wald
Confidence limits
Wald
P-value
3 (8.9%) – – – – 0.0890⁎
6 (6.9%) vs HSF 0.76 0.56 to 1.04
48 (7.0%) – – – – 0.0057
(11.4%) vs No PU 1.83 1.16 to 2.87
(12.4%) vs No PU 1.83 1.09 to 3.09
04 (7.1%) – – – – 0.3025
(10.6%) vs Written 1.34 0.90 to 1.99
(8.7%) vs Written 1.23 0.79 to 1.91
16 (7.2%) – – – – 0.6182
(9.0%) vs Secondary care hospital 1.06 0.71 to 1.58
(10.3%) vs Secondary care hospital 1.26 0.79 to 1.99
(7.5%) – – – – 0.5070
4 (8.3%) vs No 1.15 0.82 to 1.61
.3%) vs No 0.38 0.05 to 2.94
.0%) vs No 2.02 0.43 to 9.45
67 (7.7%) – – – – 0.5688
(8.6%) vs No 1.09 0.75 to 1.57
.3%) vs No 2.91 0.35 to 24.51
.0890.
ieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
a: Cumulave Incidence for development of 
PU Category>=2 by 30 day final follow-up
b;Cumulave Incidence for development of PU 
Category >=2 in treatment phase 
c: Cumulave Incidence for development of 
PU Category ≥1 by 30 day final follow-up 
d: Cumulave Incidence for development of 
PU Category ≥3 by 30 day final follow-up 
Fig. 2. a-d: Survival analysis (Cumulative incidence functions for time to development of PUs).
9J. Nixon et al. / EClinicalMedicine xxx (xxxx) xxxcompared to the PRESSURE 1 trial [8] and importantly comparable
across groups. Of note, however, is that the reason for first mattress
change was imbalanced across groups with a higher proportion of pa-
tient and ward led changes from APMs due to comfort and to aidmove-
ment/rehabilitation and a higher proportion of ward led changes from
HSF due to clinical condition, suggesting issues with equipoise amongst
clinical staff who ‘upgraded’ from HSF where patient condition deterio-
rated, patient preference for HSF in relation to comfort and both ward
and patient preference for HSF where patient rehabilitation was a ther-
apy priority. Analyses of the Per Protocol Population which retained
only patients who were compliant with their mattress allocation were
consistent with the primary ITT analyses suggesting that these issues
did not impact on the overall trial conclusions.
Risk factors found to be predictive of PU development in the ad-
justed analysis (Tables 8a–8c in eDocument 8: Additional results tables)Please cite this article as: J. Nixon, I.L. Smith, S. Brown, et al., Pressure Rel
Clinical and Health ..., , https://doi.org/10.1016/j.eclinm.2019.07.018are in linewith previouswork and adds to the growing body of evidence
that a key risk factor in immobile patients is skin status including pres-
ence of Category 1 and Category 2 PU [6,9,12].
No safety concerns were indicated for either APMs or HSF. Concerns
expressed in previous research by patients about feeling unsafe on
APMs [8] were not reflected in falls which were balanced across groups
and consistent with those reported in acutely ill hospital populations
[27] and community dwelling settings.
The trial recruitedmore slowly than originally anticipated leading to
a smaller sample size than the planned maximum sample size (2029
compared to 2954 patients), with fewer events (160 compared to
588) and was therefore underpowered under the original trial design
assumptions. Under the revised design, the trial had 80% power for de-
tecting a difference of 4% betweenmattress groups assuming an overall
event rate of 10% with corresponding hazard ratio of 0.652. The overallieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
Fig. 3.Moderator analysis (Forest plots of effect size within subgroups).
10 J. Nixon et al. / EClinicalMedicine xxx (xxxx) xxxevent rate observed was lower at 7.9% with an absolute difference of
2.0% between mattress groups, and corresponding hazard ratio of 0.76.
The a priori discussionswith the TMGon the revisedminimumclinically
important difference for varying overall event rates (3.3% difference for
10% event rate, 2.5% difference for 5% event rate — see Methods and
eDocument 5) suggest that the difference observed may not be consid-
ered to be clinically important. If APMswere allocated to patients fulfill-
ing the trial inclusion criteria, the difference equates to a Number
Needed to Treat (NNT) of 50. Thatmeans that for every 50 patients allo-
cated an APM it will benefit only 1 patient.
The event rate (7.9%) was considerably lower than the sample size
estimate of 20.5%, based upon contemporary studies [7,8,13]. A key
question is whether the low rate was because: the patient population
was ‘low risk’ due to issues around selection bias and/or; it reflects gen-
eral improvements in clinical practice resulting from national level PU
improvement targets.
Recruitment of 40.7% of eligible patients is in line with the contem-
porary studies and in terms of ‘low risk’, despite a lack of equipoise by
ward staff (i.e., unwilling to change mattress) the randomised patient
population were similar to the previous study populations [8,13] and
characterised by acute illness, old age, high levels of pre and post
randomisation falls, and high levels of adverse skin status at baseline,
with higher proportions of patients lacking capacity [8].
The impact of general improvements in practice resulting from na-
tional targets is difficult to elicit from national monitoring, due to prob-
lems of data accuracy [2] and difficult interpretation of AE data [28]. A
key observation is the low proportion of patients with a Category 1 PU
at baseline who subsequently developed a new Category 2 PU (11.4%)
compared to other studies which report rates of circa 33% [8,12,13].
Overall, the conclusion drawn is that the patient population were
high risk and that the low incidence observed reflected the prevailing
improvements in PU prevention care in the participating centres.
A key issue raised by members of the Pressure Ulcer Research Ser-
vice User Network during a results interpretation event was ‘given the
low incidence and the disadvantages of APMs in terms of impact upon
independent movement and comfort, who will benefit most fromPlease cite this article as: J. Nixon, I.L. Smith, S. Brown, et al., Pressure Rel
Clinical and Health ..., , https://doi.org/10.1016/j.eclinm.2019.07.018APMs’. As previously indicated the adjusted analysis indicates that a
key predictor of new Category 2 PU development in the study popula-
tion characterised by high levels of immobility, was the presence of Cat-
egory 1 and Category 2 PUs at baseline. In addition, the moderator
analysis was included in order to explore the potential benefit of
eachmattress on patients with known PU risk factors. Direct applica-
tion of this analysis to practice must be undertaken with caution
since it was exploratory and interactions with mattress allocation
were non-significant, but the results suggest that the impact of al-
tered and Category 1 PU skin status, complete immobility, nutri-
tional deficits and the vulnerability afforded by lack of capacity
may be modifiable as risk factors through use of the APMs. Given
the low event rate this may help clinicians considering the trade-
offs between risks and benefits of mattress allocation and frequency
of repositioning decisions.
The trial was planned as a double-triangular group sequential trial,
however, independent monitoring of the event rate and a slower than
planned recruitment rate led to a funder requested unplanned interim
analysis and trial modification with one final analysis.
Due to clinical difficulties in concealing the mattress type, a limita-
tion was the lack of blind outcome assessment. However, the blinded
central photograph reviewdid not identify any systematic bias concerns
as a result of the lack of blinding. This work will underpin the design of
blinded endpoint assessment in future trials.
Interpretation of the trial results is based on the primary endpoint
at post treatment 30 days final follow-up with the treatment phase
sensitivity analysis used to support these findings. This is the first
study to include a longer-term perspective post-treatment phase
follow-up [7]. The treatment phase endpoint could be considered
more clinically meaningful due to the majority of Category ≥2 PUs
developing within this phase (83%), the relevance of the outcome
to the institution providing the mattress intervention and the differ-
ent patient pathways following the treatment phase and associated
discharge. However, the longer term outcome provides a realistic es-
timate of effectiveness within current in-patient and community
services.ieving Support Surfaces for Pressure Ulcer Prevention (PRESSURE 2):
11J. Nixon et al. / EClinicalMedicine xxx (xxxx) xxxIn high risk patients (acutely ill in-patients who were bedfast/
chairfast and/or had an existing Category 1 PU or pain on a PU skin
site), we found insufficient evidence of a difference in PU development
at the end of trial follow-up. However, APMs did confer a small treat-
ment phase benefit. Overall the APM compliance and very low PU inci-
dence rate observed (7.9%) and small differences between mattresses
indicates the need for improved indicators for targeting of APMs and
individualised decision making taking into account patient preferences
(comfort/movement ability), rehabilitation needs and the presence of
risk factors which may be modifiable through APM allocation.
Future research should consider the primacy given to treatment phase
endpoint, an updated estimate of the event rate, and focusing on groups
of patients identified as potentially benefittingmore fromAPMcompared
toHSF to confirmwhether there is a true treatment effect in these groups.
However it is recognised that recruitment to a trial in these patient groups
is likely to be challenging based on the experiences of this trial.
The findings provide the RCT evidence to underpin current guide-
lineswhich recommend the use of HSF for patients at risk of PU and con-
sideration of ‘high tech’ mattresses where HSF is failing. This study will
inform recommendation revisions and the grade of evidence on which
recommendations are based. Current device regulations fall short in
the requirement for evidence of clinical effectiveness and can result in
widespread adoption of ‘high tech’ solutions prior to demonstrated clin-
ical or patient benefit.
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